$CLMT

Calumet Net Loss Narrows In Q2

Calumet, Inc. (CLMT) reported Q2 net loss of $95.9 million, or $1.09 per share, versus $147.9 million, or $1.70 per share, a year earlier. Net sales rose to $1,445.1 million from $1,026.6 million. The company cited higher revenue and a smaller operating loss, plus derivative unrealized gains and RIN-related non-cash expense. CLMT traded at $40.70 premarket, down 2.82% on Nasdaq.

Original reporting
Published Aug 7, 2026, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 2:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Calumet Net Loss Narrows In Q2 — source image
Decision brief

The 30-second read

$CLMTNeutralLow
01

Why it matters

The quarter shows a smaller net loss versus the prior year, but the magnitude of non-cash RINs expense and an unrealized derivatives gain suggests earnings quality and comparability remain central to investor interpretation.

02

Market read

Traders may reassess near-term sentiment around CLMT based on the reported earnings drivers and the stock’s pre-market decline.

03

What to watch

Without cash flow, guidance, or realized derivative performance, the market may overreact to non-cash items and underweight operational trends.

Relevance 5/10Novelty 4/10Timing: pre-market today

Background

Calumet, Inc. released second-quarter financial results, including net loss, sales, and key line-item drivers tied to derivatives and RINs-related expenses.

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Calumet reported Q2 net loss of $95.9M and $1.445B sales, with derivatives and RINs non-cash expense driving results.

Expected impact

Near-term volatility likely tied to how investors interpret RINs-related non-cash expense and derivative mark-to-market effects.

Evidence & confidence

The article provides the core quarterly figures and identifies the main drivers, but lacks guidance, cash flow detail, or segment breakdown to gauge forward earnings power.

Market effects

Highlights ongoing earnings sensitivity for refiners/renewables-linked credits to RINs accounting and derivative marks.

None specified.

None specified.

Counterpoint

The year-over-year net loss narrowing could indicate improving underlying operations despite accounting-driven noise from RINs and derivatives.

Key entities

  • Calumet, Inc.

    Reported Q2 net loss of $95.9M, sales of $1,445.1M, and identified derivatives and RINs-related non-cash expense as major drivers.

Related articles

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.

$CLMTMed

Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.

$CLMTMed

Why Calumet Stock Was a Major Winner on Wednesday

Calumet (CLMT) shares rose more than 4% after the company said two wholly owned subsidiaries will redeem $100 million of senior notes due 2028, paying about 102.4% of par. Calumet also noted it reduced borrowings on its revolving credit facility in Q2, as part of a deleveraging plan.

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.